[1]全养雅,张彩英.基于Hippo-YAP/TAZ途径探讨丹参酮ⅡA对肝硬化大鼠肝纤维化的改善作用实验研究[J].陕西医学杂志,2026,(6):754-760.[doi:DOI:10.3969/j.issn.1000-7377.2026.06.006]
　QUAN Yangya,ZHANG Caiying.Improvement effect of Danshenide ⅡA on liver fibrosis in liver cirrhosis rats based on Hippo-YAP/TAZ pathway[J].,2026,(6):754-760.[doi:DOI:10.3969/j.issn.1000-7377.2026.06.006]
点击复制

基于Hippo-YAP/TAZ途径探讨丹参酮ⅡA对肝硬化大鼠肝纤维化的改善作用实验研究

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2026年6期
页码:
754-760
栏目:
基础研究
出版日期:
2026-06-05

文章信息/Info

Title:
Improvement effect of Danshenide ⅡA on liver fibrosis in liver cirrhosis rats based on Hippo-YAP/TAZ pathway
作者:
全养雅; 张彩英
（湖南省第二人民医院 湖南省脑科医院消化内科，湖南 长沙 410007）
Author(s):
QUAN Yangya; ZHANG Caiying
(Department of Gastroenterology，Hunan Provincial Second People’s Hospital，Changsha 410007，China)
关键词:
肝硬化; 肝纤维化; 丹参酮ⅡA; 肝星状细胞; Yes相关蛋白; 含PDZ结合基序的转录共激活因子; 大鼠
Keywords:
Liver cirrhosis; Liver fibrosis; Tanshinone ⅡA; Hepatic stellate cells; Yes-associated protein; Transcriptional coactivator with PDZ-binding motif; Rats
分类号:
R 575.2
DOI:
DOI:10.3969/j.issn.1000-7377.2026.06.006
文献标志码:
A
摘要:
目的：探讨丹参酮ⅡA(Tan ⅡA)对肝硬化大鼠肝脏纤维化的改善作用，并基于Hippo-Yes相关蛋白(YAP)/含PDZ结合基序的转录共激活因子(TAZ)途径分析其潜在作用机制。方法：腹腔注射40%四氯化碳花生油混悬液诱导肝硬化大鼠模型。将造模成功的大鼠随机分为模型组、Tan ⅡA-L组（5 mg/kg Tan ⅡA灌胃）、Tan ⅡA-M组（10 mg/kg Tan ⅡA灌胃）和Tan ⅡA-H组（20 mg/kg Tan ⅡA灌胃），每组15只。另随机选取15只SD大鼠作为对照组。连续干预8周。ELISA试剂盒检测大鼠血清中肝功能相关指标[丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)和总胆红素（TBIL）]；HE染色和Masson染色观察大鼠肝组织病理学变化；免疫组织化学染色检测肝脏纤维化相关蛋白[转化生长因子-β1（TGF-β1）和平滑肌肌动蛋白α(α-SMA)]蛋白表达；免疫荧光检测肝星状细胞（HSC）细胞α-SMA表达强度；Western blot检测肝组织Hippo-YAP/TAZ通路相关蛋白表达。结果：与对照组比较，模型组大鼠肝组织损伤加重，血清ALT、AST、TBIL表达水平，肝组织α-SMA表达强度及α-SMA、TGF-β1、p-YAP、p-TAZ、CTGF蛋白水平明显增加（均P<0.05）。与模型组比较，Tan ⅡA-L组、Tan ⅡA-M组和Tan ⅡA-H组肝组织损伤减轻，血清ALT、AST、TBIL表达水平，肝组织α-SMA表达强度及α-SMA、TGF-β1、p-YAP、p-TAZ、CTGF蛋白水平明显降低（均P<0.05），其中Tan ⅡA-H组整体效果最显著。结论：Tan ⅡA能够有效改善大鼠肝纤维化程度，抑制大鼠HSC活化，其作用机制可能与抑制Hippo-YAP/TAZ信号通路有关。
Abstract:
Objective:To investigate the effect of tanshinone ⅡA (Tan ⅡA) on liver fibrosis in rats with liver cirrhosis，and to analyze its potential mechanism based on the Hippo-YAP/TAZ pathway.Methods：A liver cirrhosis rat model was established by intraperitoneal injection of 40% carbon tetrachloride in peanut oil suspension.The successfully modeled rats were randomly divided into the model group，the Tan ⅡA-L group (intragastric administration of 5 mg/kg Tan ⅡA)，the Tan ⅡA-M group (intragastric administration of 10 mg/kg Tan ⅡA)，and the Tan ⅡA-H group (intragastric administration of 20 mg/kg Tan ⅡA)，with 15 rats in each group.Another 15 SD rats were randomly selected as the control group.The intervention lasted for 8 weeks.The ELISA kits were used to detect the liver function-related indicators (ALT，AST，and TBIL) in the rat serum.HE staining and Masson staining were used to observe the pathological changes of the rat liver tissue.Immunohistochemical staining was used to detect the protein expression of liver fibrosis-related proteins (TGF-β1，α-SMA).Immunofluorescence was used to detect the expression intensity of α-SMA in HSC.Western blot was used to detect the expression of Hippo-YAP/TAZ pathway-related proteins in liver tissue.Results:Compared with the control group，the liver tissue damage in the model group was more severe，and the expression levels of serum ALT，AST，and TBIL，the expression intensity of α-SMA，and the protein levels of α-SMA，TGF-β1，p-YAP，p-TAZ，and CTGF in liver tissues were significantly increased (all P<0.05).Compared with the model group，the liver tissue damage in the Tan ⅡA-L group，Tan ⅡA-M group，and Tan ⅡA-H group was alleviated，and the expression levels of serum ALT，AST，and TBIL，the expression intensity of α-SMA，and the protein levels of α-SMA，TGF-β1，p-YAP，p-TAZ，and CTGF in liver tissues were significantly decreased (all P<0.05).Among them，the overall effect of the Tan ⅡA-H group was the most significant.Conclusion:Tan ⅡA can effectively improve the degree of liver fibrosis in rats，inhibit the activation of HSCs，and its mechanism of action may be related to the inhibition of the Hippo-YAP/TAZ signaling pathway.

参考文献/References:

[1]马琦阳，潘高展.大黄素对肝硬化大鼠肝功能及肠黏膜屏障损伤的改善作用[J].国际检验医学杂志，2025，46(8)：960-964.[2]LI S，SUN X，CHEN M，et al.Liver fibrosis conventional and molecular imaging diagnosis update[J].J Liver，2019，8(1)：236.[3]SULTAN L R，GRASSO V，JOSE J，et al.Advanced tchniques for liver fibrosis detection：Spectral photoacoustic imaging and superpixel photoacoustic unmixing analysis for collagen tracking[J].Sensors (Basel)，2024，24(14)：4617.[4]ZHANG W，GAO K，BAI Y，et al.Wedelolactone attenuates liver fibrosis and hepatic stellate cell activation by suppressing the Hippo pathway[J].Rejuvenation Res，2024，27(6)：207-219.[5]CHEN Y，GAO W K，SHU Y Y，et al.Mechanisms of ductular reaction in non-alcoholic steatohepatitis[J].World J Gastroenterol，2022，28(19)：2088-2099.[6]闫佳兰，高利涛，甄宁，等.电针联合丹参酮ⅡA经Hippo信号通路改善脑缺血再灌注损伤大鼠神经细胞凋亡的机制研究[J].实用临床医药杂志，2025，29(8)：58-64.[7]AZAM M，HIRA K，QURESHI S A，et al.Ameliorative effect of marine macroalgae on carbon tetrachloride-induced hepatic fibrosis and associated complications in rats[J].Turk J Pharm Sci，2022，19(2)：116-124.[8]高月彩，苏明，刘荣格.丹参酮ⅡA调控NF-κB信号通路对急性呼吸衰竭大鼠炎症因子及细胞凋亡的影响[J].现代药物与临床，2025，40(1)：37-43.[9]秘相征，郭源泉，许华.Tan ⅡA联合还原型谷胱甘肽治疗抗肿瘤药致急性肝损伤的效果评价[J].现代肿瘤医学，2020，28(17)：3046-3049.[10]郝健亨，王海军，曹玉霞，等.丹参酮ⅡA治疗非酒精性脂肪性肝病的网络分析及实验验证[J].中国老年学杂志，2024，44(21)：5243-5249.[11]肖燕婷，黄淡霞，黄凤蕊，等.丹参酮ⅡA对D-半乳糖胺诱导的大鼠急性肝衰竭保护作用机制研究[J].实用临床医药杂志，2025，29(7)：58-63，70.[12]GAO Y，WU H，LUO Y，et al.Mechanisms of dihydromyricetin for improving hepatic fibrosis through the integration of metabolomics and gut microbiota[J].Am J Chin Med，2025，53(3)：889-908.[13]HUANG Y，LIANGPUNSAKUL S，RUDRAIAH S，et al.HMGB2 is a potential diagnostic marker and therapeutic target for liver fibrosis and cirrhosis[J].Hepatol Commun，2023，7(11)：e0299.[14]WANG X，CAI B，YANG X，et al.Cholesterol stabilizes TAZ in hepatocytes to promote experimental non-alcoholic steatohepatitis[J].Cell Metab，2020，31(5)：969-986.[15]CHU Y H，PANG B Y，YANG M，et al.The intervention of curcumin on rodent models of hepatic fibrosis：A systematic review and meta-analysis[J].PLoS One，2024，19(5)：e0304176.[16]ZHANG H，QIU J，ZHAO Q，et al.Tanshinone ⅡA alleviates bleomycin-induced pulmonary fibrosis by inhibiting Zbtb16[J].Pulm Pharmacol Ther，2024，84：102285.[17]宋海容，邱建利，李灿灿，等.丹参酮ⅡA对胆道闭锁肝纤维化大鼠SMAD4、SMAD7及Ⅰ型胶原蛋白的影响[J].安徽医学，2024，45(5)：537-541.[18]张君，崔益华，黄成，等.山奈酚调节Hippo信号通路对脊髓星形胶质细胞氧化损伤的影响[J].陕西医学杂志，2025，54(10)：1311-1315，1348.[19]RUSSELL J O，CAMARGO F D.Hippo signalling in the liver：Role in development，regeneration and disease[J].Nat Rev Gastroenterol Hepatol，2022，19(5)：297-312.[20]ALSAMMAN S，CHRISTENSON S A，YU A，et al.Targeting acid ceramidase inhibits YAP/TAZ signaling to reduce fibrosis in mice[J].Sci Transl Med，2020，12(557)：eaay8798.[21]WANG Y，STOESS C，HOLZMANN G，et al.Signalling of the neuropeptide calcitonin gene-related peptide (CGRP) through RAMP1 promotes liver fibrosis via TGFβ1/Smad2 and YAP pathways[J].Exp Cell Res，2024，442(1)：114193.[22]XIE L，CHEN H，ZHANG L，et al.JCAD deficiency attenuates activation of hepatic stellate cells and cholestatic fibrosis[J].Clin Mol Hepatol，2024，30(2)：206-224.[23]GAO K，ZHANG W，XU D，et al.Chikusetsusaponin Ⅳa targeted YAP as an inhibitor to attenuate liver fibrosis and hepatic stellate cell activation[J].Chin Med，2025，20(1)：36.[24]何德全.丹参酮ⅡA通过调控Hippo-YAP信号通路改善动脉粥样硬化炎症反应[D].广州：南方医科大学，2023.[25]MA Z，HU N，ZHENG L，et al.Tanshinone ⅡA alleviates tri-ortho-cresyl phosphate-induced ovarian damage through Hippo signaling pathway activation in mice[J].J Ovarian Res，2025，18(1)：85.

相似文献/References:

[1]徐志刚,曹 罡,程传涛,等.CTRP3通过TGF-β1/Smad 信号通路减弱肝星状细胞活性机制研究*[J].陕西医学杂志,2020,49(5):523.
　XU Zhigang,CAO Gang,CHENG Chuantao,et al.Mechanism of CTRP3 attenuating hepatic stellate cell activation through TGF-β1/Smad signal pathway[J].,2020,49(6):523.
[2]蔡碧莲,文亦磊△,罗伟生△.大鼠肝纤维化实验动物模型的构建*[J].陕西医学杂志,2020,49(6):659.[doi:DOI:10.3969/j.issn.10007377.2020.06.005]
[3]艾丁丁,罗伟生△,蒋云霞.动物肝纤维化模型建立研究进展*[J].陕西医学杂志,2020,49(7):907.[doi:DOI:10.3969/j.issn.10007377.2020.07.038]
　AI Dingding,LUO Weisheng,JIANG Yunxia..Progress in the establisment of animal liver fibrosis model[J].,2020,49(6):907.[doi:DOI:10.3969/j.issn.10007377.2020.07.038]
[4]韩艳珍,单铁英,李 伟,等.口服枸杞多糖对小鼠肝纤维化组织基质金属蛋白酶-2及基质金属蛋白酶-2抑制剂水平影响的实验研究[J].陕西医学杂志,2021,50(3):276.[doi:DOI:10.3969/j.issn.1000-7377.2021.03.005]
　HAN Yanzhen,SHAN Tieying,LI Wei,et al.Effects of Lycium barbarum polysaccharide on the levels of MMP-2 and TIMP-2 in mice with liver fibrosis[J].,2021,50(6):276.[doi:DOI:10.3969/j.issn.1000-7377.2021.03.005]
[5]王小芳,张利军.可溶性人髓系细胞触发受体1、可溶性血红蛋白清道夫受体、降钙素原表达水平对肝硬化合并自发性细菌性腹膜炎的诊断价值[J].陕西医学杂志,2021,50(12):1525.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.014]
[6]郭武辉,张 华.血清T淋巴细胞亚群检测在肝硬化合并真菌性血流感染中的诊断价值[J].陕西医学杂志,2021,50(12):1570.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.026]
　GUO Wuhui,ZHANG Hua.Diagnostic value of serum T lymphocyte subsets detection in liver cirrhosis complicated with fungal bloodstream infection[J].,2021,50(6):1570.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.026]
[7]姜 帆,李春香,李忠原.超声双模态影像技术联合动态增强磁共振检查对大鼠早期肝纤维化的评估价值实验研究[J].陕西医学杂志,2023,52(3):273.[doi:DOI:10.3969/j.issn.1000-7377.2023.03.006]
　JIANG Fan,LI Chunxiang,LI Zhongyuan.Evaluation value of ultrasound dual-modality imaging technique combined with DCE-MRI in rats with early hepatic fibrosis[J].,2023,52(6):273.[doi:DOI:10.3969/j.issn.1000-7377.2023.03.006]
[8]樊江浩,王 嘉,万 杰,等.肝硬化门静脉血栓抗凝治疗有效性及安全性Meta分析[J].陕西医学杂志,2023,52(4):487.[doi:DOI:10.3969/j.issn.1000-7377.2023.04.028]
　FAN Jianghao,WANG Jia,WAN Jie,et al.Efficacy and safety of anticoagulant therapy for portal vein thrombosis in liver cirrhosis:a meta-analysis[J].,2023,52(6):487.[doi:DOI:10.3969/j.issn.1000-7377.2023.04.028]
[9]刘 俊,曾 龙,高 云,等.长链非编码RNA YAF2-AS1通过调控微小RNA-141-3p表达抑制肝星状细胞活化实验研究[J].陕西医学杂志,2023,52(9):1120.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.002]
　LIU Jun,ZENG Long,GAO Yun,et al.Long-chain non-coding RNA YAF2-AS1 inhibits activation of hepatic stellate cells by regulating expression of microRNA-141-3p[J].,2023,52(6):1120.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.002]
[10]刘 杰,闵林玲,潘 金,等.经颈静脉肝内门腔静脉分流术与经皮肝穿刺胃冠状静脉栓塞术治疗肝硬化食管胃底静脉曲张破裂出血疗效对比研究[J].陕西医学杂志,2023,52(9):1191.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.017]
　LIU Jie,MIN Linling,PAN Jin,et al.Comparative study of TIPS and PTVE in treatment of esophageal and gastric varices bleeding in liver cirrhosis[J].,2023,52(6):1191.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.017]

备注/Memo

备注/Memo:
湖南省自然科学基金资助项目（2024JJ51192）
更新日期/Last Update: 2026-06-05